Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab combinations vs pembrolizumab in first-line PD-L1 high metastatic NSCLC
jRCT2080224136Phase 3Terminated
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Nov 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Regeneron Pharmaceuticals. Started Nov 2018; status: terminated.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080224136.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224136.